AFLIBERCEPT

Brand name:

• Afqlir® Enzeevu™

Pharmaceutical company:

SANDOZ PTY LTD

Condition/indication:
(therapeutic use)

• Macular oedema secondary to retinal vein occlusion (RVO) Diabetic macular oedema (DMO) Subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD)

PBAC Submission type:

New PBS listing (–)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – July 2025

Related medicines:

--

Submission received for:

July 2025 PBAC meeting

Opportunity for consumer comment:

Open 02/04/2025 and close 28/05/2025 (see PBS Website)

PBAC meeting:

Held on 09/07/2025

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

14/08/2025

Lodgement of required documentation:

22/08/2025

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 04/11/2025

Status:

Finalised

7Government processes:

Commenced on 07/11/2025

8Medicine listed on the PBS:

Has not yet occurred

---